Letter | Published:

This is an unedited manuscript that has been accepted for publication. Nature Research are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Mechanism of parkin activation by PINK1

Nature (2018) | Download Citation

Abstract

Mutations in the E3 ubiquitin ligase parkin (PARK2) and the protein kinase PINK1 (PARK6) are linked to autosomal-recessive juvenile Parkinsonism (AR-JP)1,2, and at the cellular level cause defects in mitophagy, the cellular process that organises destruction of damaged mitochondria3,4. Parkin is autoinhibited, and requires activation by PINK1, which phosphorylates Ser65 in ubiquitin and in the parkin ubiquitin-like (Ubl) domain. Parkin binds phospho-ubiquitin, which enables efficient Parkin phosphorylation; however, the enzyme remains autoinhibited with an inaccessible active site5,6. It is unclear how phosphorylation of parkin activates the molecule. Here we follow the activation of full-length human parkin by hydrogen deuterium exchange mass spectrometry, and reveal large-scale domain rearrangement in the activation process, in which the phospho-Ubl rebinds to the parkin core, and releases the catalytic RING2 domain. A 1.8 Å crystal structure of phosphorylated human parkin reveals the binding site of the phosphorylated Ubl on the unique parkin domain (UPD), involving a phosphate-binding pocket lined by AR-JP mutations. Strikingly, a conserved linker region between Ubl and UPD acts as an activating element (ACT) that contributes to RING2 release by mimicking RING2 interactions on the UPD, explaining further AR-JP mutations. Our data unveil how autoinhibition in parkin is resolved, and suggest how parkin ubiquitinates its substrates via an untethered RING2 domain. This opens exciting new avenues to design parkin activators for clinical use.

  • Subscribe to Nature for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Author information

Affiliations

  1. Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, UK

    • Christina Gladkova
    • , Sarah Maslen
    • , J. Mark Skehel
    •  & David Komander

Authors

  1. Search for Christina Gladkova in:

  2. Search for Sarah Maslen in:

  3. Search for J. Mark Skehel in:

  4. Search for David Komander in:

Corresponding author

Correspondence to David Komander.

Supplementary information

  1. Supplementary Fig. 1

    Uncropped versions of SDS-PAGE gels

  2. Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41586-018-0224-x

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.